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Failure of clinical trials of nonviral vector-mediated gene 
therapy arises primarily from either an insufficient trans-
gene expression level or immunostimulation concerns 
caused by the genetic information carrier (e.g., bacteria-
generated, double-stranded DNA (dsDNA)). Neither of 
these issues could be addressed through engineering-
sophisticated gene delivery vehicles. Therefore, we 
propose a systemic delivery of chemically modified mes-
senger RNA (mRNA) as an alternative to plasmid DNA 
(pDNA) in cancer gene therapy. Modified mRNA evaded 
recognition by the innate immune system and was less 
immunostimulating than dsDNA or regular mRNA. More-
over, the cytoplasmic delivery of mRNA circumvented 
the nuclear envelope, which resulted in a higher gene 
expression level. When formulated in the nanoparticle 
formulation liposome-protamine-RNA (LPR), modified 
mRNA showed increased nuclease tolerance and was 
more effectively taken up by tumor cells after systemic 
administration. The use of LPR resulted in a substantial 
increase of the gene expression level compared with 
the equivalent pDNA in the human lung cancer NCI-
H460 carcinoma. In a therapeutic model, when modi-
fied mRNA encoding herpes simplex virus 1-thymidine 
kinase (HSV1-tk) was systemically delivered to H460 
xenograft-bearing nude mice, it was significantly more 
effective in suppressing tumor growth than pDNA.
Received 9 July 2012; accepted 31 October 2012; advance online 
publication 11 December 2012. doi:10.1038/mt.2012.250
IntroductIon
Messenger RNA (mRNA) is frequently applied as a gene delivery 
molecule in the field of cancer immunotherapy and stem cell-based 
biomedical research as an alternative to plasmid DNA (pDNA).1–4 
As a direct source of gene products, mRNA has several advan-
tages, including a lack of requirement for nuclear entry,5 which 
poses a significant barrier to pDNA delivery, especially in nondi-
viding cells. mRNA also has a negligible chance of integrating into 
the host genome,6 avoiding aberrant transcription and expression 
of oncogenes caused by insertional mutagenesis. However, what 
prevents mRNA from becoming a conventional tool for gene ther-
apy is its vulnerability to the ubiquitously expressed nuclease and 
the immune stimulation that substantially suppresses expression 
efficiency and elicits an immune toxicity in the host.
Chemically modified mRNA synthesized in vitro and com-
bined with naturally occurring modified ribonucleotides, has over-
come the aforementioned shortcomings and shown great promise 
as a powerful therapeutic tool for gene therapy.4,7,8 Kormann et al. 
(2011) reported in vivo gene therapy using naked chemically modi-
fied mRNA as a therapeutic.7 The modification of mRNA through 
the incorporation of two nucleotide analogs substantially decreased 
activation of the innate immune response through the toll-like recep-
tor (TLR) pathway, concomitantly increasing the intracellular stabil-
ity. A single intramuscular injection of modified mRNA resulted in 
an elevated expression of mouse erythropoietin for up to 14 days,7 
revealing the potential in vivo application of this technology.
In this study, we attempted to systemically deliver modified 
mRNA to tumor sites. This was achieved by rationally addressing 
the challenges to systemic delivery of mRNA from several perspec-
tives. First, mRNA transcripts were constructed with experimen-
tally established structural modifications for enhanced stability 
and translatability.4 Second, the immune-stimulating property of 
in vitro transcription (IVT) mRNA was suppressed by completely 
substituting cytidine triphosphate and uridine triphosphate with 
5-methylcytidine triphosphate and pseudouridine (ψ) triphos-
phate, respectively. Third, modified mRNA was encapsulated in 
a lipid/protamine/mRNA (LPR) formulation, which rendered 
the mRNA with high stability during circulation and possibly 
improved the pharmacokinetics after systemic administration.9
The functions of multiple components in the formulation of 
the LPR attributed to an improvement in its gene delivery effi-
ciency. Two components played a role in protecting the LPR and 
prolonging its circulation; the polycationic protamine condenses 
nucleic acid into nanosized complexes to protect it from nuclease 
degradation and heavily coated polyethylene glycol (PEG) enables 
the nanoparticles to evade nonspecific uptake by the reticuloen-
dothelial system10 to prolong circulation time after intravenous 
injection. The cationic liposomal membrane facilitates endosomal 
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escape and the cytosolic release of the cargo. And finally, the low 
molecular weight anisamide (AA) that was grafted on the distal 
end of PEG facilitates receptor-mediated internalization of the 
nanoparticles into the sigma receptor overexpressing cancer cells.
The present study was initiated with a formulation optimiza-
tion study, followed by the assessment of in vitro transfection assays. 
The in vivo biodistribution of LPR and the tumor-specific expres-
sion of a model gene were studied using an in vivo imaging system. 
Systemic toxicity and the immune-stimulating property of the LPR 
nanoparticles were also examined. As a proof of concept, we deliv-
ered a therapeutic mRNA encoding the suicide gene herpes simplex 
virus 1-thymidine kinase (HSV1-tk) and demonstrated anticancer 
effect in a xenograft model. The results revealed the superior thera-
peutic value of the modified mRNA compared with dsDNA.
results
Modified mrnA is formulated in lPr nanoparticles 
with favorable physicochemical properties for 
systemic delivery
Modified mRNA was prepared with a T7 polymerase-based 
IVT kit with a yield of ~60 μg/reaction. In the self-assembly, 
 liposome-based, core membrane nanoparticle formulation, the pre-
formed DOTAP (1,2-dioleoyl-3-trimethylammonium- propane)/
cholesterol (1:1 molar ratio) liposome interacted  electrostatically 
with the mRNA–protamine complex, inducing lipid bilayers to col-
lapse on the core structure.9,11–13 As a result,  spherical, solid, lipo-
somal nanoparticles with a core/membrane  structure were formed. 
The core supported and stabilized the  liposomal  membrane to 
allow up to 15% (molar ratio) of DSPE  (1,2- distearoy-phosphatidy
lethanolamine)-PEG and DSPE-PEG-AA to be inserted for stealth 
and targeting purposes, respectively (Figure 1a). LPRs of various 
compositions were prepared according to an experimental design 
provided for by a screening matrix (Supplementary Figure S1a), 
such that the optimal formulation could be evaluated based on 
particle size, zeta potential, and in vitro transfection efficiency. The 
mean hydrodynamic particle size and surface charge of the LPR 
were determined using dynamic light scattering and laser doppler 
electrophoresis techniques, respectively (Supplementary Figure 
S1b). The LPR prepared using formulation 6 resulted in a nano-
particle with the desired size (ca. 60 nm) and a relatively low zeta 
potential (ca. 25 mV) (Figure 1b), an indication of a high degree of 
charge shielding by PEGylation. The size of the LPR was confirmed 
with transmission electron microscopy (Figure 1c). To examine the 
stability of the LPR in the presence of serum and test whether the 
formulation could protect mRNA from RNAse, mRNA or LPR was 
incubated in the serum followed by an analysis of agarose gel elec-
trophoresis. It was observed that the mRNA stayed encapsulated in 
the LPR despite the presence of serum protein, which protects the 
cargo from nuclease degradation (Supplementary Figure S1c). 
These favorable properties allow mRNA to maintain its biological 
integrity before being delivered intracellularly to the site of action.
lPr efficiently delivers modified mrnA into cancer 
cells for transgene expression
We evaluated the biological activity of the LPR in vitro. A well-





























































Figure 1 Preparation and characterizations of the lPr. (a) Illustration of formulating-modified mRNA into LPR. Anionic mRNA was mixed with 
different amounts of protamine and DOTAP/cholesterol liposome to form the core/membrane structure complex. The nanoparticles were then 
PEGylated by post-insertion. (b) Representative histogram showing the size distribution and zeta potential of nanoparticle formulated with formula-
tion 6. (c) Nanoparticles observed with transmission electron microscope (TEM). Bar: 0.2 μm. Inset bar: 50 nm. DOTAP, 1,2-dioleoyl-3-trimethylam-
monium-propane; DSPE, 1,2-distearoyl-phosphatidylethanolamine; LPR, lipid/protamine/mRNA; mRNA, messenger RNA; PEG, polyethylene glycol.
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was transfected with enhanced green fluorescent protein (GFP) 
mRNA-loaded LPR that had been prepared with various for-
mulations (LPR 1–9). Transfection efficiency was quantitatively 
determined by flow cytometry analysis 24 hours post-transfection. 
It was demonstrated that the LPR was able to transfect 68–78% 














































































































































































Figure 2 In vitro transfection studies of the lPr. (a) Microscopic observation of cellular uptake and expression efficiency after administration of LPR or LPD. 
Nucleic acids (mRNA or pDNA) were labeled with Cy3 and the expression of transgene could be visualized by green fluorescent protein. (b) Quantification 
of cellular uptake and expression level with flow cytometry analysis. Percent of cells that took up nanoparticles and percent of cells that expressed transgenes 
were compared. The data were reported as mean ± SD. (c) Quantification of mean fluorescence intensity (MFI) with flow cytometry analysis. Expression 
level of each transfected cell, which was reflected by MFI, was compared for the H460 cells transfected with LPR. The data were reported as mean ± SD. 
(d) Epifluorescence microscopic photographs of transfected H460 cells in the presence of different concentrations of haloperidol. (e) Validation of targeting 
ability of anisamide ligand by transfecting H460 cells in the presence of sigma receptor ligand, haloperidol. Total green fluorescent protein and percent 
of transfected cells for the H460 cells transfected with LPR with and without targeting ligand, or in the presence of different concentration of haloperidol, 
was determined by flow cytometry analysis. The data were reported as mean ± SD. (f) Expression duration study with LPR loaded with luciferase mRNA. 
H460 cells were transfected with LPR or LPD loaded with equivalent amount of chemically modified mRNA, conventional mRNA, and pDNA that express 
firefly luciferase. Samples were assayed at different timepoints for luciferase expression level. The data were reported as mean ± SD. (g) Dose-response 
study and dose-toxicity study for LPR nanoparticle. H460 cells were transfected with various doses of LPR nanoparticle. Toxicity was monitored with 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay while transfection level was monitored by flow cytometry analysis. GFP, green fluorescent 
protein; LPR, lipid/protamine/mRNA; mRNA, messenger RNA; pDNA, plasmid DNA.
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transfected cells (Supplementary Figure S1d). Out of all the for-
mulations with high gene delivery efficiency, the LPR-6 was able 
to transfect ca. 68% of H460 cells with a high expression level of 
GFP. The compact particle size of LPR-6 indicated a complete 
condensation of mRNA. Moreover, there are extensive studies 
with regard to the correlation between the nanoparticle size and 
tumor penetration efficiency, all of which pinpoint that smaller 
size allows extravasation and deeper penetration into the crowded 
interstitial space in the tumor tissue.15–18 The relatively low zeta 
potential of this formulation would minimize the absorption of 
serum protein during circulation. Therefore, this formulation was 
chosen for in vivo delivery based on its colloidal properties and in 
vitro transfection activity.
nanoparticle-formulated modified mrnA is superior 
to pdnA for gene therapy
In order to compare the transfection efficiency between modi-
fied mRNA or pDNA delivered by LPR (or LPD), we investigated 
the cellular uptake of LPR (or LPD) with Cy3-labeled mRNA or 
pDNA. The expression level was determined by quantifying the 
GFP expression mediated by mRNA or pDNA after delivery 
into H460 cells using the same formulation. The results showed 
that the uptake of the targeted LPR were highly efficient in vitro, 
regardless of the type of cargo encapsulated. Nevertheless, a sig-
nificantly larger proportion of cells expressed GFP when they 
had been delivered mRNA than when delivered pDNA (86 and 
12%, respectively) (Figure 2a,b). When individual cell expression 
of GFP was evaluated by flow cytometry, the mean fluorescence 
intensity of LPD-transfected cells was three times higher than that 
of LPR-transfected cells (Figure 2c).
AA-modified lPr facilitates the internalization of 
nanoparticles into sigma receptor expressing cells
We demonstrated that the LPR was internalized through sigma 
receptors by performing an inhibition assay. The assay was per-
formed by pretreating the cells with haloperidol (a sigma-1 recep-
tor ligand) to saturate the receptors before administration of the 
LPR. The results indicated that the percent of transfected cells 
was reversely proportional to the concentration of the compet-
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Figure 3 In vivo biodistribution and transfection studies of the lPr. (a) Biodistribution of Texas red-labeled LPR in the major organs of H460 
xenograft-bearing nude mice 4 hours post-administration. (b) Expression profile of mcherry RFP in major organs of H460 xenograft-bearing nude 
mice 24 hours post-administration. Modified mRNA encoding mcherry RFP was formulated in LPR nanoparticle and intravenously administered to 
H460 xenograft-bearing nude mice. The transgene expression in major organs was determined with Kodak in vivo imaging system. (c) Confocal 
microscopic image of cryosection from RFP-expressing tumor tissue after in vivo transfection. (d) Quantification of luciferase activity in major organs 
and tumor tissue 24 hours post-administration of LPR loaded with modified mRNA encoding luciferase. Animals were killed 24 hours after intravenous 
injection of LPR. Tissue lysate was subjected to luciferase assay to quantify the expression level of transgene. (e) Serum cytokine levels of LPR-treated 
CD-1 mice were examined by ELISA assay. Sera were collected from CD-1 mice that received single dose injection of LPR 4 hours post-injection. The 
cytokine levels were assayed with ELISA kits, respectively. The data were reported as mean ± SD. IFN, interferon; IL, interleukin; LPR, lipid/protamine/
mRNA; mRNA, messenger RNA; PBS, phosphate-buffered saline; pDNA, plasmid DNA; RFP, red fluorescent protein; TNF, tumor necrosis factor.
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Figure 4 systemic delivery of modified mrnA encoding HsV-tk in the lPr coupled with GcV for cancer gene therapy. (a) MTS cell prolifera-
tion assay used to determine the killing efficiency of LPR (HSV-tk)/GCV in vitro. The data were reported as mean ± SD. (b) Flow cytometry analysis of 
H460 cells treated with LPR (HSV-tk)/GCV followed by PI/annexin V staining. Cells were transfected with LPR (HSV-tk) nanoparticles in combination 
with GCV. Timeline of cell apoptosis was determined by PI/annexin-V double staining followed by flow cytometry analysis. (c) Proliferation capacity 
for the survival cells after HSV-tk/GCV therapy determined by clonogenic assay. The number was normalized against untreated group. The data were 
reported as mean ± SD. (d) Tumor growth inhibition study on H460 tumor xenograft. Tumor size was monitored every 3 days during the drug treat-
ment. Tumor volumes were calculated as ½ × length × width × height. The data were reported as mean ± SEM (n = 4–6). (e) Tumor volumes from 
animals at end point of the experiment. Each symbol represents an individual mouse. Horizontal lines indicate mean values. (f) TUNEL assay show-
ing the apoptosis degree of tumors harvested from end point of the tumor growth inhibition experiment. Con, control; GCV, ganciclovir; HSV-tk, 
herpes simplex virus-thymidine kinase; LPR, lipid/protamine/mRNA; mRNA, messenger RNA; PI, propidium iodide; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling.
Molecular Therapy  vol. 21 no. 2 feb. 2013 363
© The American Society of Gene & Cell Therapy
Systemic Delivery of Modified mRNA to Tumor
for the group treated with 50 µmol/l haloperidol. However, no sig-
nificant difference between the gene expression levels of the trans-
fected cells was observed. In addition, LPR without AA showed a 
significantly compromised transfection capacity, likely due to the 
lack of entry to the cells through receptor-mediated endocytosis.
To compare the translatability of modified mRNA with that 
of regular mRNA and pDNA, an LPR loaded with 0.5 μg IVT-
modified mRNA or pDNA encoding firefly luciferase was used to 
transfect H460 cells. Luciferase is a short-lived enzyme with an 
half-life of about 3 hours,19 making it advantageous for  monitoring 
the real-time transgene expression profile. Results revealed that 
LPR-treated cells had a rapid luciferase expression (1,513 pg/mg) 
4 hours post-transfection and reached peak expression 18 hours 
post-transfection (3,495 pg/mg). However, pDNA-mediated 
expression did not reach a comparable level until 18 hours post-
transfection (1,686 pg/mg) (Figure 2f). Both of the expression 
levels from mRNA and pDNA started to decline 48 hours post-
transfection.
Toxicity is also a critical parameter used to evaluate a therapeu-
tic agent for clinical use. By incubating H460 cells with different 
concentrations of LPR and performing an 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, we dem-
onstrated that the LPR induced minimal in vitro cytotoxicity at 
a concentration of up to 5 µg/ml mRNA (Figure 2g). As little as 
100 ng of modified mRNA was able to transfect up to 66% of cells 
seeded in a 96-well plate. The especially high efficacy and low tox-
icity shown in these studies suggest an excellent therapeutic index 
for in vivo studies.
lPr accumulates in the tumor and results in model 
gene expression after systemic administration
The in vivo biological activity of LPR was assessed in H460 xeno-
graft-bearing nude mice. A significant amount of particle accumu-
lation, represented by Texas-red fluorescent dye, was observed in 
the tumor 4 hours post-injection. However, there was a relatively 
small portion of nanoparticles that were nonspecifically taken up 
by the liver, lung, and kidneys (Figure 3a). To evaluate the transfec-
tion capacity of the LPR in vivo, mRNA for mcherry red fluorescent 
protein (RFP) was encapsulated into the LPR. RFP was selected 
for imaging purpose due to the low background autofluorescence 
signal compared with that of the commonly used enhanced GFP. 
The results showed a strong fluorescence signal in the tumor, while 
all the major organs only displayed background level fluorescence 
intensity compared with the phosphate-buffered saline (PBS)-
treated control group (Figure 3b). The expression of RFP was also 
 confirmed by confocal microscopic observation of cryosections 
from RFP-expressing tumor tissue (Figure 3c). A quantitative 
luciferase activity assay was conducted after systemic administration 
of LPR loaded with luciferase mRNA (Figure 3d). Tumor-targeted 
delivery of luciferase mRNA produced luciferase activity in tumors 
(25 pg/mg) that was higher than in other tissues (0–2 pg/mg).
lPr induces lower cytokine level than lPd in cd-1 
mice
As was observed in the biodistribution study, the liver and kidneys 
were the two major organs that took up the LPR. It is reported that 
systemic administration of cationic lipid/nucleic acid complexes 
could induce hepatic toxicity.20 Therefore, it was necessary to 
check the liver and kidney damage after the systemic administra-
tion of nanoparticles. CD-1 mice were intravenously injected with 
the regular dose of LPR for tumor delivery (equivalent to 10 µg 
modified mRNA in each injection) for three consecutive days. 
The serum alanine transaminase and aspartate transaminase lev-
els were assayed as markers for liver infraction. The blood urea 
nitrogen level, a kidney damage indicator, was also assayed. The 
data demonstrated that, in nanoparticle-treated mice, all three 
parameters fell within the normal range (Supplementary Figure 
S1f). This result, coupled with the hematoxylin and eosin stains of 
major organs (Supplementary Figure S1e), indicated that mini-
mal, if any, toxicity had been caused to the liver, kidney, and other 
organs by the LPR after repeated systemic administration.
To evaluate if IVT mRNA synthesized with modified nucle-
otides was useful in reducing inflammatory response induced spe-
cifically by single-stranded RNA, sera were collected from CD-1 
mice 4 hours post-injection. The cytokine levels were evaluated 
by ELISA assay (Figure 3e). The results demonstrated that LPR 
formulation loaded with the modified mRNA induced negligible 
levels of tumor necrosis factor-α and interleukin (IL)-6; the level 
of IL-12 was close to that of the untreated mice. The only elevated 
cytokine was interferon (INF)-α (~490 pg/ml). In contrast, LPR 
loaded with unmodified mRNA induced relatively high level of 
IL-6 (~1,495 pg/ml), IFN-α (~1,953 pg/ml), and IL-12 (~1,950 pg/
ml). The pDNA-loaded LPD induced high levels of IFN-α (~5,109 
pg/ml) and IL-12 (~5,653 pg/ml), although IL-6 elevation was not 
observed.
lPr delivers modified mrnA encoding HsV1-tk to 
xenograft in nude mice and induces apoptosis and 
inhibits the tumor growth
HSV1-tk/ganciclovir (GCV), one of the most widely used suicide 
gene/prodrug systems in cancer gene therapy, was used as a model 
therapeutic gene to test our delivery system. The in vitro cell-kill-
ing efficiency of LPR loaded with HSV1-tk mRNA combined with 
GCV was evaluated using an MTT assay. The higher percent of 
transfected cells mediated by modified mRNA led to a significant 
killing rate (73%). In contrast, the expression of tk driven by the 
cytomegalovirus promoter mediated by pDNA achieved only 23% 
cell death (Figure 4a). No significant cytotoxicity was observed in 
cells treated only with GCV. The timeline of cell death after treat-
ment with LPR (HSV-tk)/GCV was investigated with annexin-V 
and propidium iodide staining followed by flow cytometry analy-
sis. The data revealed that the treatment induced early apoptosis 
of 70% of H460 cells within 24 hours of transfection and that the 
cells reached the late apoptosis stage within 48 hours (Figure 4b). 
In a clonogenic assay, which was used to determine the prolifera-
tion capacity of the surviving cells after treatment, barely 1% of 
the cells recovered and formed colonies (Figure 4c).
A H460 xenograft animal model was also utilized to test the 
antitumor efficacy of LPR (HSV-tk)/GCV in vivo. In this study, 
treatment with LPR (HSV-tk)/GCV resulted in a significant inhi-
bition of tumor growth compared with the untreated group (P = 
0.0003) (Figure 4d). Furthermore, surface modification of the 
targeting ligand AA allowed for more efficient tumor growth inhi-
bition (P = 0.008). As was consistent with the in vitro data, LPD 
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(HSV-tk) nanoparticles showed an inferior inhibition efficacy to 
LPR (HSV-tk) combined with GCV (P = 0.0006). To assess the 
amount of apoptosis caused by the treatment, a terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
was performed on harvested tumor tissue samples. A larger area 
of apoptosis was observed in tumors treated with LPR (HSV-tk)/
GCV, demonstrating that the nanoparticles loaded with modi-
fied mRNA were able to impact a larger population of the tar-
get cells (Figure 4f). We also tracked the weight of mice during 
the treatment. The results did not show any significant change 
in the weight of the animals, an indication of low systemic toxic-
ity (Supplementary Figure S1g). The expression of HSV-tk was 
confirmed by western blot analysis using goat anti-tk polyclonal 
antibodies (Supplementary Figure S1h).
dIscussIon
The advent of mRNA synthesized with naturally occurring ribo-
nucleotides opens a new window of opportunity for using modi-
fied mRNA as a novel therapeutic agent to treat cancer and other 
diseases. The incorporation of chemically modified nucleotides 
into mRNA has substantially reduced the innate antiviral immune 
response, leading to high translation efficiency and relieving con-
cerns regarding the safety of the therapy. The main objective of 
our study was to demonstrate the feasibility of systemically deliv-
ering the modified mRNA to the tumor site for transgene expres-
sion with high efficiency using a lipidic nanodevice.
With the formulation screened by physicochemical and bio-
logical tests, mRNA could be condensed into nanoparticles smaller 
than 100 nm in diameter, a size suitable to fit into a clathrin-
coated pit in order to be internalized through receptor-mediated 
endocytosis.21 The zeta potentials were moderate, an indication of 
a high degree of PEGylation. The hydrophilic PEG molecules were 
expected to screen the positive charge by DOTAP/cholesterol lipid 
bilayer, thereby preventing the attachment of serum protein and 
minimizing uptake of nanoparticles by the reticuloendothelial 
system. The colloidal stability of nanoparticles in the presence of 
serum, as well as the protection of mRNA from RNAse digestion, 
increased the likelihood of mRNA being delivered to the tumor 
with full integrity after a long circulation time.
As a direct source of gene product, there is still a question 
whether modified mRNA is more efficacious (i.e., generating 
more therapeutic protein products) than pDNA. When electropo-
ration is exploited to deliver exogenous mRNA into hematopoi-
etic cells, mRNA electroporation has shown a higher and more 
sustainable expression than DNA electroporation.6 However, 
when a nonviral vector is introduced into the systemic delivery of 
modified mRNA, the intricacy of the nonviral vector per se leads 
to the uncertainties regarding gene transfer efficiency. Cationic 
liposomes are very efficient DNA-based transfection reagent. 
However, mRNA delivered by lipoplex is suggested to lead to a 
poor transfection efficiency compared with pDNA22 probably due 
to the higher- binding affinity between the cationic liposome and 
single-stranded RNA than pDNA which reduces the accessibil-
ity of RNA to intracellular translation machinery.23 Therefore the 
assumption that cytoplasmic delivery of mRNA results in a higher 
expression level than pDNA as a result of obviating the necessity 
for nuclear entry should not be easily made without the context.24 
When we compared the in vitro expression levels of mRNA and 
pDNA delivered by LPR (or LPD), which were identically for-
mulated in nanoparticles that displayed similar physicochemical 
properties. Although H460 cells took up comparable numbers of 
nanoparticles loaded with mRNA or pDNA, only about 10% of 
cells that took up LPD particles expressed GFP. In contrast, ca. 
90% of cells that took up LPR expressed GFP. The high transfection 
efficiency mediated by mRNA suggested that the release of nucleic 
acids from the vector did not seem to be the rate-limiting step in 
that mRNA or pDNA was condensed by a low molecular weight 
polycation (protamine, 4 kDa).24 Since endosome escape facili-
tated by the cationic lipid DOTAP was the same for both nano-
particles,25 the large discrepancy in the percent of transfected cells 
probably resulted from the barriers to nuclear entry for pDNA-
mediated transfection.26 Other factors such as favorable transcrip-
tion conditions or egression efficiency of RNA transcripts from 
the nucleus27 could account for lower pDNA-mediated transfec-
tion efficiency, as well.
The translatability of mRNA and pDNA, on the other hand, 
was reflected by the average fluorescence intensity of transfected 
cells. pDNA exhibited a fluorescence intensity 2.5 times higher 
than that of mRNA. The observation could be explained by the 
fact that pDNA continues to generate copies of mRNA transcripts 
until the promoter is transcriptionally inactivated28 or the pDNA 
is lost during cell proliferation. Moreover, the rapid increase in 
expression caused by modified mRNA (4 hours post-transfection) 
and the delayed pDNA-based expression (18 hours post-transfec-
tion) suggested that pDNA expression was cell cycle dependent26 
and mRNA was not24 because the doubling time for H460 cell is 
23 hours.29 As was expected, delivery of modified mRNA resulted 
in a pattern of rapid, transient, and cell cycle-independent expres-
sion profiles.
In addition to the cytoplasmic translation, low immune stimu-
lation also makes modified mRNA advantageous for gene deliv-
ery. IVT mRNA has been intensively used in dendritic cell-based 
immunotherapy largely due to the fact that RNA transfection alone 
could cause dendritic maturation. It has been reported that single-
stranded RNA could activate TLR7, a mechanism that the innate 
immune system exploits to detect an RNA virus infection.30 It is 
reported that the secondary structure of exogenous mRNA is likely 
to activate PKR, a global repressor of protein translation,31 result-
ing in a low transgene expression. In mammalian cells, RNA from 
various organelles are heavily and diversely modified,32 allowing 
the innate immune system to distinguish foreign RNA from self-
RNA. To suppress the properties that cause immune stimulation, 
we substituted cytidine triphosphate and uridine triphosphate 
with naturally occurring 5-methylcytidine and pseudouridine 
(ψ) triphosphate, respectively, while synthesizing IVT RNA. 
Incorporation of the modified ribonucleotides renders a disguise 
for exogenous RNA, reducing the ability to activate TLR3, TLR7, 
TLR9, retinoic acid inducible gene I, and PKR.33 The results from 
the ELISA assays demonstrated that the chemically modified 
mRNA formulated in LPR reduced the innate immune response 
in the animals. The relatively low level of IFN-α was probably due 
to the presence of dsDNA or other impurities according to the 
work published by Karikó et al.33 It is reported that the presence of 
such impurities in the IVT mRNA would elevate tumor necrosis 
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factor-α and IFN-α levels and this particular immune-stimulating 
property could be eliminated by high-performance liquid chro-
matography purification of mRNA.33 This low immune stimula-
tion property overcomes the obstacle to the clinical application of 
pDNA caused by unmethylated CpG motifs. Finally, the relatively 
low cellular toxicity and high efficacy opens a broad therapeutic 
window for the in vivo application of LPR.
Solid tumor tissues are distinguished from normal tissues by 
its elevated level of vascular permeability and a lower lymphatic 
drainage.34 This tumor-specific property has been indicated as the 
major cause for the passive targeting (the enhanced permeability 
and retention effect) that causes the accumulation of macromol-
ecules or nanoparticles after systemic administration of the nano-
particles. Although the in vitro data pinpointed that the presence 
of AA at the distal end of LPR creates selectivity and facilitates the 
internalization of nanoparticles into the targeted cells, it is still argu-
able that ligands have a major impact on the tumor accumulation 
of the administered nanoparticles.35 Because the sigma receptor is 
not only expressed in the tumor tissues but also in all major organs 
(data not shown), we can assume that the high accumulation of LPR 
in tumor sites was predominantly due to long-circulating properties 
and the enhanced permeability and retention effect. This result was 
consistent with the previous data acquired from the LPD system. 
Densely PEGylated lipidic nanoparticles exhibited higher passive 
targeting to tumors with leaky vessels because of their extended 
blood circulation half-life.36 After LPR penetrates into the tumor 
mass, the targeting ligand on the surface can then facilitate the 
internalization, resulting in the expression of the transgene.
To demonstrate a proof of concept of the therapeutic efficacy 
of the LPR nanoparticle for cancer therapy, we delivered a suicide 
gene into a xenograft mouse model. This HSV-tk/GCV suicide gene 
therapy has been extensively studied in the clinical trials on prostate 
cancers, ovarian cancers, and brain cancers.37 In most of the clinical 
trials, viral vectors are more favorable because they can provide a 
sufficient gene expression level, despite the safety concerns arising 
from the use of viral vectors in gene therapy.38,39 The idea behind the 
therapy is that the expression of HSV-tk sensitizes transfected tumor 
cells to the exposure of prodrug GCV. Because of the transfer of 
GCV triphosphate via gap junctions or apoptosis bodies, both cells 
expressing the transgene and their neighboring cells will undergo 
apoptosis. This process has been termed the “bystander effect”.37 The 
bystander effect was observed in our in vitro experiments; only ca. 
12% of H460 cells were transfected by LPD, but the results of the 
MTT assay indicated a killing efficiency of ca. 23%. However, as the 
transfection efficiency of the LPR-mediated delivery approached 
70%, the marginal benefit acquired from the “bystander effect” 
reduced due to the shortage of untransfected cells in vitro.
In vivo transfection does not seem to be mediated by the same 
limiting factor as in vitro delivery. The larger the amount of trans-
fection was in vivo, the larger the cell population that was killed 
through the bystander effect. In the tumor inhibition study, there 
was a statistically significant (P = 0.0006) difference between LPD- 
and LPR-treated tumor sizes, which was considered a reflection of 
the transfection efficiency. The incorporation of nucleotide analogs 
into dsDNA results in DNA chain breaks and mitochondrial dam-
age that initiates HSV-tk/GCV-induced apoptosis.37 TUNEL anal-
ysis revealed a significantly larger population of cells undergoing 
apoptosis treated by LPR compared with LPD. However, the tk 
expression levels from homogenates of tumor tissue were not dif-
ferent based on a western blot analysis (Supplementary Figure 
S1h). Collectively, it could be deduced that larger populations of 
cells expressing moderate levels of enzymes were more efficacious 
than smaller populations of cells expressing high levels of enzymes 
in regards to this specific gene therapy. It should also be noted that, 
in the case of intraperitoneal administration, rapid expression of 
the transgene mediated by modified mRNA allowed an immediate 
action of a small molecule drug, GCV. The expression of tk increases 
before the GCV is eliminated via renal clearance, creating favorable 
conditions for converting the prodrug into the active form. This 
advantage could be utilized in combination therapies when gene 
therapy and chemotherapy are employed in tandem to kill cancer 
cells via different mechanisms of action. Any synergistic effects may 
reduce the possibility of cells developing drug resistance.
conclusion
In summary, we have demonstrated an LPR-mediated systemic 
delivery of modified mRNA into targeted tumor cells for transgene 
expression and therapeutic efficacy. Chemically modified mRNA 
seems to be a superior genetic information carrier to pDNA in terms 
of both efficacy and safety. This study demonstrates the applicabil-
ity of modified mRNA in targeted gene therapy in vivo. Although 
relatively transient, expression mediated by modified mRNA was 
rapid and robust, free of concerns for chromosomal integration, 
and immune response. These features indicate great potential for 
future clinical trials. Apart from cancer gene therapy, the systemic 
delivery of modified mRNA may also be of great convenience and 
advantageous in the development of regenerative medicine for 
the treatment of diabetes, spinal cord injuries, myocardial infarc-
tion, and neurologic syndromes. Furthermore, LPR systems could 
potentially be equipped with different targeting ligands to be able to 
deliver genes to various cell types for diverse therapeutic purposes.
MAterIAls And MetHods
Materials. DOTAP and DSPE-N-(methoxy (polyethyleneglycol)-2000) 
ammonium salt (DSPE-PEG2000) were purchased from Avanti Polar 
Lipids (Alabaster, AL). Cholesterol and protamine sulfate (fraction × 
from salmon) was purchased Sigma-Aldrich (St Louis, MO). All the other 
chemicals were purchased from Sigma-Aldrich unless otherwise men-
tioned. DSPE-PEG-AA was synthesized according to the previously estab-
lished protocol.40
Preparation of modified mRNA. Modified mRNA was prepared with 
a T7 polymerase-based IVT kit (Ambion, Austin, TX) according to the 
manufacturer’s manual. The open-reading frame of the gene of interest 
was cloned into a pcDNA3.1 vector under the regulation of T7 promoter. 
The untranslated region and gene of interest was amplified by PCR reac-
tion with 5′ primer CTAGAGAACCCACTGCTTACTGGCTTATCG 
and 3′ primer T120GCGTCGACACTAGTTCTAGACCCT. The ampli-
cons were used as templates for IVT. The RNA was synthesized with 
MEGAscript T7 kit (Ambion, Austin, TX) with 1.6 μg template and 
7.5 mmol/l adenosine triphosphate, 1.5 mmol/l guanosine triphosphate, 
6 mmol/l 3′-0-Me-m7G(5′)ppp(5′)G (anti-reverse cap analog), 7.5 mmol/l 
5-methylcytidine triphosphate, and 7.5 mmol/l pseudouridine triphos-
phate (TriLink Biotechnologies, San Diego,CA). Reactions were incubated 
at 37 °C for 4 hours. mRNA was purified by using the Ambion MEGAclear 
kit (Ambion). Although the incorporation of antireverse cap analog 
366 www.moleculartherapy.org  vol. 21 no. 2 feb. 2013
© The American Society of Gene & Cell Therapy
Systemic Delivery of Modified mRNA to Tumor
drastically reduced the yield to ca. 60 μg per 40 μl reaction, the blocking 
of 3′ hydroxyl of methylated G makes 3′ hydroxyl of unmethylated G 
available for initiation, which guarantees the biological activity of capped 
mRNA transcripts. Vectors carrying enhanced GFP (Addgene 26822) 
and mcherry RFP (Addgene 26823) gene were purchased from Addgene 
(Cambridge, MA). Open-reading frame of HSV-tk was purchased from 
Invivogen (San Diego, CA).
Preparation of liposome and LPR. DOTAP and cholesterol (1:1, mol/mol) 
were dissolved in chloroform and solvent was removed under reduced 
pressure. The lipid film is hydrated overnight with distilled water to make 
the final concentration 10 mmol/l DOTAP and cholesterol. The liposome 
was sequentially extruded through 400, 200, 100, and 50 nm polycarbonate 
membranes (Millipore, Billerica, MA) in order to form 80–100 nm uni-
lamellar liposomes. LPR core was formed by mixing 146 μl of solution A 
(10 μg mRNA) and 146 μl of solution B (3 μl of 2 mg/ml protamine, 12 μl 
of 10 mmol/l DOTAP/cholesterol liposome, and 131 μl distilled water). 
The mix solution was incubated at room temperature for 10 minutes. 
PEGylation was performed by adding 4 μl DSPE-PEG (10 mg/ml) and 
4 μl DSPE-PEG-AA (10 mg/ml) to the LPR core and incubating the mix at 
50 °C for 15 minutes. The size and surface charge of the nanoparticles were 
determined by Malvern ZS90 (Malvern, Worcestershire, UK).
In vitro transfection and uptake study. Ninety-six well plates were 
seeded with 104 cells per well. Particle equivalent to 0.5 μg of modified 
mRNA encoding enhanced GFP was added to each well in the presence of 
OptiMEM medium and kept in the incubator. The medium was replaced 
with full medium 4 hours post-transfection. The transfection efficiency 
was determined with FACSCanto (BD Biosciences, San Jose, CA). For the 
uptake study, a 10% FAM-labeled oligonucleotides (IDT, Coralville, IA) 
mixture was combined with mRNA as a fluorescent marker, the percent 
of uptake was determined 2 hours post-transfection by FACSCanto. Cells 
transfected with modified mRNA or pDNA encoding luciferase were sub-
jected to luciferase assay (Promega, Madison, MI) according to manufac-
turer’s instruction at different timepoints. Cells transfected with mRNA 
encoding HSV-tk were subjected to MTT cell proliferation assay 2 days 
post-transfection; 20 μl of 12 mmol/l MTT solution was added to each well 
in fresh phenol-red free full media. The reaction was stopped by remov-
ing media after 2 hours incubation at 37 °C incubator. The formazan was 
solubilized by adding 200 μl dimethyl sulfoxide and shaken at room tem-
perature for 30 minutes. The absorbance was read at 570 nm to determine 
the cytotoxicity.
In vivo transfection study. Nanoparticles equivalent to 10 μg of mRNA 
prepared as aforementioned were injected intravenously into the subcu-
taneous tumor-bearing nude mice. Twenty percent Texas-red labeled oli-
gonucleotide (IDT) was mixed with mRNA as a fluorescent marker for 
the nanoparticles biodistribution study. Four hours post-injection, animals 
were killed to collect organs (heart, liver, spleen, lung, kidneys, tumor). 
Organs were imaged with Kodak in vivo imaging system FX Pro (Kodak, 
Rochester, NY). To study transfection in vivo, nanoparticles equivalent to 
10 μg of mRNA encoding mcherry RFP were intravenously administered 
to subcutaneous tumor-bearing nude mice. Mice were killed 24 hours 
post-injection and the organs were collected to image RFP expression. In 
the case of luciferase, nanoparticles equivalent to 20 μg of mRNA encoding 
luciferase were intravenously administered to nude mice bearing subcuta-
neous tumors. Mice were killed 24 hours post-injection. Organs and tumor 
tissues were homogenized and the tissue lysates were subject to luciferase 
assay(Promega) according to manufacturer’s instruction. A standard curve 
was plotted by using luciferase standard in the H460 tumor or tissue lysates 
without luciferase. All the relative luminescence units were converted to 
amount of luciferase enzyme according to the standard curve. All animal 
protocols were approved by the University of North Carolina at Chapel 
Hill’s Institutional Animal Care and Use Committee.
Aspartate transaminase, alanine transaminase, blood urea nitrogen 
assay and cytokine induction assay. CD-1 mice were intravenously 
injected with LPR (equivalent to 10 μg) for three consecutive days. On 
day 4, mice were killed and sera were collected for aspartate transaminase, 
alanine transaminase, and blood urea nitrogen assay performed by UNC 
facility. Organs were collected and fixed with 4% paraformaldehyde in 
PBS overnight before stained with hematoxylin and eosin by University of 
North Carolina histology facility. For the cytokine induction assay, 4 hours 
post-injection of LPR (equivalent to 10 μg), CD-1 mice were killed and sera 
were collected for IL-6, IL-12, IFN-α, and TNF-α level with ELISA assay kit 
(BD Biosciences, San Diego, CA) according to manufacturer’s manual.
Clonogenic assay. Nanoparticle equivalent to 0.5 μg of HSV-tk mRNA 
or control mRNA was administered to 104 H460 cells seeded in 96-well 
plate. Four hours post-transfection, medium was refreshed with RPMI-
1640 supplemented with 50 μmol/l of GCV. Forty-eight hours post-trans-
fection, cells were trypsinized and live cells were harvested and counted in 
the presence of trypan blue (Sigma-Aldrich). Two hundred live cells from 
each treatment were plated in a 6-well plate. One week later, medium was 
removed and cells were washed with Dulbecco’s PBS for two times before 
stained with 0.25% crystal violet blue in 50% ethanol.
Tumor inhibition assay. Athymic nude mice of 6–8 weeks old were inocu-
lated with 5 × 106 H460 cells on the hind legs. Nanoparticles equivalent to 
10 μg of mRNA or pDNA was prepared as aforementioned were injected 
intravenously every other day for five treatments since the tumor volume 
reached 50 mm3. Meanwhile, mice received 25 mg/kg GCV twice a day for 
10 days of treatment. Tumor size was measured with digital caliper (Thermo 
Fisher Scientific, Pittsburgh, PA) and animal weight was monitored every 3 
days. Tumor volume was calculated as (½ × length × width × height).
TUNEL assay. Tumor tissue was harvested at the end point of tumor inhi-
bition study and was fixed with 4% paraformaldehyde before embedded 
in paraffin. After deparaffinization, section was stained with DeadEnd 
Fluoremetric TUNEL Assay kit (Promega) according to the manufacturer’s 
manual. The image was acquired through Nikon epifluorescence micro-
scope (Nikon Instruments, Melville, NY).
Western blot analysis. Five milligram of tumor was homogenized in 300 μl 
of RIPA buffer (150 mmol/l NaCl, 1.0% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mmol/l Tris, pH 8.0). The sample was spun down 
at top speed with a tabletop centrifuge for 10 minutes. Supernatant was 
quantified with bovine serum albumin assay (Pierce Biotech, Rockford, IL) 
and 50 μg of protein was loaded on a NuPAGE Novex Bis-Tris 4–12% gel 
(Invitrogen, Grand Island, NY) and transferred to a polyvinylidene fluoride 
membrane. The membrane was blocked with PBS-Tween with 5% skim 
milk for 1 hour followed by overnight incubation with primary antibodies 
such as mouse anti HSV1-tk (vL-20) antibody (1:200 dilution; Santa Cruz 
Biotechnology, Santa Cruz, CA) and mouse anti β-actin (C-4) (1:1,000 
dilution; Santa Cruz Biotechnology). After wash with PBS-Tween, second-
ary antibody goat-mouse IgG2a-HRP (1:1,000; Santa Cruz Biotechnology) 
was applied to the membrane for 1 hour. The protein was detected with 
Supersignal chemiluminescence substrate (Pierce Biotech).
Statistical analysis. Percentages of GFP-positive cells and mean fluorescence 
intensities were calculated by BD CellQuest (BD Biosciences) software. 
Statistical analysis will be undertaken using Prism 5.0c Software (GraphPad 
Software, La Jolla, CA). A two tailed t-test or an one-way analysis of vari-
ance was performed when comparing two groups or more than two groups, 
respectively. Statistical significance was defined by a value of P < 0.05.
suPPleMentArY MAterIAl
Figure S1. Optimization of the formulation and evaluations of 
 systemic toxicity of the LPR.
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